Payment overview · 2025
General Payments
$43,829.07
242 reported records · 20 companies
Healthcare provider profile · identity verified
Jason Faller, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · NEW YORK, NY · NPI 1558352740
Verified facts
What the public records show
CMS Open Payments records show Jason Faller, M.D. received $43,829.07 in general payments during 2025 across 242 reported records.
ABBVIE INC. accounted for 62.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Actemra, Otezla.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Otezla by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Actemra by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27,314.14 | 62.3% | 69 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $7,973.15 | 18.2% | 31 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $6,053.56 | 13.8% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $393.83 | 0.9% | 22 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $370.86 | 0.8% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $368.18 | 0.8% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $365.58 | 0.8% | 20 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $274.25 | 0.6% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $202.63 | 0.5% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.83 | 0.4% | 8 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.26 | 0.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $71.09 | 0.2% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $45.90 | 0.1% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $31.20 | 0.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $22.18 | 0.1% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $19.20 | 0.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $18.84 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.97 | 0.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $15.53 | 0.0% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $14.89 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,822.50 | 19 |
| Food and Beverage | $5,460.58 | 204 |
| Travel and Lodging | $2,656.96 | 16 |
| Consulting Fee | $879.38 | 2 |
| Education | $9.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $15,721.71 | 45 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $11,592.43 | 24 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $7,692.61 | 18 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $6,053.56 | 18 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $393.83 | 22 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $370.86 | 12 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $365.58 | 20 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $284.88 | 14 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $267.39 | 19 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $231.80 | 8 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $178.96 | 9 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $160.73 | 7 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $135.63 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $72.62 | 3 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $72.26 | 3 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $54.63 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $36.78 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| Binosto Normalized: binosto |
Drug | Radius Health, Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $6.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Actemra actemra |
2025 | Actemra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 285 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 36 |
| Prednisone | Prednisone | 141 | 37 |
| Allopurinol | Allopurinol | 140 | 37 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 101 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 95 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 68 | 18 |
| Humira(Cf) Pen | Adalimumab | 64 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 56 | 15 |
| Metformin Hcl | Metformin Hcl | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Otezla | Apremilast | 52 | suppressed |
| Losartan Potassium | Losartan Potassium | 51 | 12 |
| Folic Acid | Folic Acid | 38 | suppressed |
| Enbrel Sureclick | Etanercept | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | 12 |
| Colchicine | Colchicine | 36 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Omeprazole | Omeprazole | 35 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 13 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 18 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 15 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Actemra | Tocilizumab | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Spironolactone | Spironolactone | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lisinopril | Lisinopril | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $43,829.07 · 242 records | ABBVIE INC. | ABRYSVO, ACTHAR, Actemra, BENLYSTA, Bimzelx, Binosto, COMIRNATY, COSENTYX, ENBREL, EVENITY, HADLIMA, KRYSTEXXA, LUPKYNIS, OPSYNVI, ORENCIA, OTEZLA, PEMGARDA, PREVNAR 20, RENFLEXIS, RINVOQ, SAPHNELO, SHINGRIX, SKYRIZI, STRENSIQ, TALTZ, TAVNEOS, TONMYA, TREMFYA, Tymlos, UPLIZNA, XELJANZ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Actemra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error